{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:05:34Z","timestamp":1790957134149,"version":"4.1.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jtha.2024.07.012","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T06:41:19Z","timestamp":1722580879000},"page":"2945-2960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Adeno-associated viral vector integration: implications for long-term efficacy and safety"],"prefix":"10.1016","volume":"22","author":[{"given":"Paul","family":"Batty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lillicrap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.07.012_bib1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.012_bib2","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.012_bib3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-associated defective virus particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"key":"10.1016\/j.jtha.2024.07.012_bib5","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1073\/pnas.55.6.1467","article-title":"Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics","volume":"55","author":"Hoggan","year":"1966","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.07.012_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jtha.2024.07.012_bib7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/cells12050785","article-title":"Various AAV serotypes and their applications in gene therapy: an overview","volume":"12","author":"Issa","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.jtha.2024.07.012_bib8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.tim.2021.09.005","article-title":"Adeno-associated virus (AAV) cell entry: structural insights","volume":"30","author":"Meyer","year":"2022","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.jtha.2024.07.012_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01220-7","article-title":"Functional roles of the membrane-associated AAV protein MAAP","volume":"11","author":"Galibert","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtha.2024.07.012_bib10","article-title":"The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication","volume":"9","author":"Cao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2024.07.012_bib11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.virol.2015.03.007","article-title":"AAV2 X increases AAV6 rep\/cap-driven rAAV production","volume":"482","author":"Cao","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.jtha.2024.07.012_bib12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ng.3893","article-title":"Identification of liver-specific enhancer-promoter activity in the 3\u2032 untranslated region of the wild-type AAV2 genome","volume":"49","author":"Logan","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtha.2024.07.012_bib13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jtha.2024.07.012_bib14","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/gt.2011.90","article-title":"Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia","volume":"19","author":"Li","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib16","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/jmv.23818","article-title":"The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals","volume":"86","author":"Mimuro","year":"2014","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jtha.2024.07.012_bib17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/rth2.12177","article-title":"Adenovirus-associated antibodies in UK cohort of hemophilia patients: a seroprevalence study of the presence of adenovirus-associated virus vector-serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A","volume":"3","author":"Stanford","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.012_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12705","article-title":"Seroprevalence to adeno-associated virus type 6 in people with hemophilia B from a UK adult cohort","volume":"6","author":"Boyce","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.012_bib19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.omtm.2022.10.014","article-title":"The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs","volume":"27","author":"Kashiwakura","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2024.07.012_bib20","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2021.287","article-title":"Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A","volume":"33","author":"Klamroth","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","article-title":"Binding and neutralizing anti-AAV antibodies: detection and implications for rAAV-mediated gene therapy","volume":"31","author":"Schulz","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib22","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3390\/v12060662","article-title":"The interplay between adeno-associated virus and its helper viruses","volume":"12","author":"Meier","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.jtha.2024.07.012_bib23","doi-asserted-by":"crossref","first-page":"14793","DOI":"10.1128\/JVI.79.23.14793-14803.2005","article-title":"Characterization of adeno-associated virus genomes isolated from human tissues","volume":"79","author":"Schnepp","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2024.07.012_bib24","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/gutjnl-2019-318281","article-title":"Adeno-associated virus in the liver: natural history and consequences in tumour development","volume":"69","author":"La Bella","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jtha.2024.07.012_bib25","doi-asserted-by":"crossref","first-page":"6096","DOI":"10.1128\/jvi.67.10.6096-6104.1993","article-title":"Features of the adeno-associated virus origin involved in substrate recognition by the viral Rep protein","volume":"67","author":"Snyder","year":"1993","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2024.07.012_bib26","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1128\/JVI.76.11.5411-5421.2002","article-title":"Efficient integration of recombinant adeno-associated virus DNA vectors requires a p5-rep sequence in cis","volume":"76","author":"Philpott","year":"2002","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2024.07.012_bib27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0092-8674(90)90526-K","article-title":"The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity","volume":"61","author":"Im","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.jtha.2024.07.012_bib28","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1073\/pnas.87.6.2211","article-title":"Site-specific integration by adeno-associated virus","volume":"87","author":"Kotin","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.07.012_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000985","article-title":"Integration preferences of wildtype AAV-2 for consensus rep-binding sites at numerous loci in the human genome","volume":"6","author":"H\u00fcser","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jtha.2024.07.012_bib30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1743-422X-11-15","article-title":"Adeno-associated virus type 2 preferentially integrates single genome copies with defined breakpoints","volume":"11","author":"Janovitz","year":"2014","journal-title":"Virol J"},{"key":"10.1016\/j.jtha.2024.07.012_bib31","doi-asserted-by":"crossref","first-page":"11253","DOI":"10.1128\/JVI.01356-14","article-title":"Adeno-associated virus type 2 wild-type and vector-mediated genomic integration profiles of human diploid fibroblasts analyzed by third-generation PacBio DNA sequencing","volume":"88","author":"H\u00fcser","year":"2014","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2024.07.012_bib32","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1128\/JVI.03419-13","article-title":"Highly divergent integration profile of adeno-associated virus serotype 5 revealed by high-throughput sequencing","volume":"88","author":"Janovitz","year":"2014","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2024.07.012_bib33","first-page":"1081","article-title":"Prevalent and disseminated recombinant and wild-type adeno-associated virus integration in macaques and humans","volume":"34","author":"Martins","year":"2023","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib34","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41586-023-06003-w","article-title":"Genomic investigations of unexplained acute hepatitis in children","volume":"617","author":"Morfopoulou","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2024.07.012_bib35","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-023-05948-2","article-title":"Adeno-associated virus 2 infection in children with non-A-E hepatitis","volume":"617","author":"Ho","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2024.07.012_bib36","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41586-023-05949-1","article-title":"Adeno-associated virus type 2 in US children with acute severe hepatitis","volume":"617","author":"Servellita","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2024.07.012_bib37","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtha.2024.07.012_bib38","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ng.3547","article-title":"Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer","volume":"48","author":"Fujimoto","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtha.2024.07.012_bib39","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1186\/s12864-021-08098-9","article-title":"Integration of adeno-associated virus (AAV) into the genomes of most Thai and Mongolian liver cancer patients does not induce oncogenesis","volume":"22","author":"Sch\u00e4ffer","year":"2021","journal-title":"BMC Genomics"},{"key":"10.1016\/j.jtha.2024.07.012_bib40","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1038\/s41388-021-01725-5","article-title":"Large-scale molecular epidemiological analysis of AAV in a cancer patient population","volume":"40","author":"Qin","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.jtha.2024.07.012_bib41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.omtm.2023.04.009","article-title":"Comparing molecular and computational approaches for detecting viral integration of AAV gene therapy constructs","volume":"29","author":"Oziolor","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2024.07.012_bib42","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1089\/hum.1997.8.6-659","article-title":"Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle","volume":"8","author":"Clark","year":"1997","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib43","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nm0397-306","article-title":"Recombinant adeno-associated virus for muscle directed gene therapy","volume":"3","author":"Fisher","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2024.07.012_bib44","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1073\/pnas.94.11.5804","article-title":"Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus","volume":"94","author":"Herzog","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.07.012_bib45","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1089\/hum.1997.8.16-1891","article-title":"Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice","volume":"8","author":"Snyder","year":"1997","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/ng0598-13","article-title":"The kinetics of rAAV integration in the liver","volume":"19","author":"Miao","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtha.2024.07.012_bib47","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1128\/JVI.73.7.5438-5447.1999","article-title":"Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver","volume":"73","author":"Nakai","year":"1999","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2024.07.012_bib48","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1128\/JVI.75.15.6969-6976.2001","article-title":"Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in\u00a0vivo","volume":"75","author":"Nakai","year":"2001","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2024.07.012_bib49","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1128\/JVI.77.6.3495-3504.2003","article-title":"Genetic fate of recombinant adeno-associated virus vector genomes in muscle","volume":"77","author":"Schnepp","year":"2003","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2024.07.012_bib50","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/sj.gt.3301541","article-title":"Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors","volume":"8","author":"Donsante","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib51","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jtha.2024.07.012_bib52","doi-asserted-by":"crossref","first-page":"11264","DOI":"10.1073\/pnas.1117032109","article-title":"Induction of hepatocellular carcinoma by in\u00a0vivo gene targeting","volume":"109","author":"Wang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.07.012_bib53","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1089\/hum.2012.112","article-title":"Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction","volume":"24","author":"Zhong","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib54","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/mt.2014.240","article-title":"Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates","volume":"23","author":"Walia","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib55","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.omtm.2019.10.016","article-title":"Pathogenesis of hepatic tumors following gene therapy in murine and canine models of glycogen storage disease","volume":"15","author":"Kang","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2024.07.012_bib56","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ymthe.2020.12.031","article-title":"Enhanced efficacy and increased long-term toxicity of CNS-directed, AAV-based combination therapy for Krabbe disease","volume":"29","author":"Li","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib57","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ymthe.2005.03.020","article-title":"No evidence for tumorigenesis of AAV vectors in a large-scale study in mice","volume":"12","author":"Bell","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib58","first-page":"69","article-title":"Hepatitis virus protein X-phenylalanine hydroxylase fusion proteins identified in PKU mice treated with AAV-WPRE vectors","volume":"12","author":"Embury","year":"2008","journal-title":"Gene Ther Mol Biol"},{"key":"10.1016\/j.jtha.2024.07.012_bib59","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/humu.21390","article-title":"Molybdenum cofactor deficiency: mutations in GPHN, MOCS1, and MOCS2","volume":"32","author":"Reiss","year":"2011","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jtha.2024.07.012_bib60","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1182\/blood-2010-08-302729","article-title":"Assessing the potential for AAV vector genotoxicity in a murine model","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.012_bib61","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1160\/TH13-02-0154","article-title":"Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in\u00a0vitro and in\u00a0vivo","volume":"110","author":"Kao","year":"2013","journal-title":"Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2024.07.012_bib62","article-title":"Assessment of vector integration of AAV5-hFIX in mice and non-human primates indicates no association with tumorigenic risk [abstract]","volume":"4","author":"Spronck","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.012_bib63","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/gt.2013.7","article-title":"No tumour-initiating risk associated with scAAV transduction in newborn rat liver","volume":"20","author":"Gauttier","year":"2013","journal-title":"Gene Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib64","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: an integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib65","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ymthe.2020.10.018","article-title":"Liver injury increases the incidence of HCC following AAV gene therapy in mice","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib66","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1016\/j.ymthe.2022.10.004","article-title":"Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma","volume":"30","author":"Kapelanski-Lamoureux","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib67","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2008-10-181479","article-title":"Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy","volume":"113","author":"Niemeyer","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.012_bib68","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A\u00a0long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtha.2024.07.012_bib69","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood.2023022589","article-title":"Vector integration and fate in the hemophilia dog liver multiple years after AAV-FVIII gene transfer","volume":"143","author":"Batty","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.012_bib70","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/mt.2011.107","article-title":"Stable human FIX expression after 0.9G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques","volume":"19","author":"Mattar","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib71","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.ymthe.2017.04.003","article-title":"In utero transfer of adeno-associated viral vectors produces long-term factor IX levels in a cynomolgus macaque model","volume":"25","author":"Mattar","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib72","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1096\/fj.201801391R","article-title":"Therapeutic expression of human clotting factors IX and X following adeno-associated viral vector-mediated intrauterine gene transfer in early-gestation fetal macaques","volume":"33","author":"Chan","year":"2019","journal-title":"FASEB J"},{"key":"10.1016\/j.jtha.2024.07.012_bib73","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/mt.2012.47","article-title":"Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver","volume":"20","author":"Nowrouzi","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib74","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib75","first-page":"425","article-title":"Rare genomic integrations of AAV5-hFVIII-SQ occur without evidence of clonal activation or gene-specific targeting","volume":"29","author":"Sullivan","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib76","first-page":"A13","article-title":"Assessment of the integration profile of self-complementary AAV vector over time in non-human primates","volume":"28","author":"McIntosh","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib77","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/s41587-023-01974-7","article-title":"Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration","volume":"42","author":"Greig","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtha.2024.07.012_bib78","doi-asserted-by":"crossref","first-page":"12991","DOI":"10.1073\/pnas.192219599","article-title":"The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion","volume":"99","author":"Lozier","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.07.012_bib79","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1055\/s-0037-1613063","article-title":"Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia","volume":"87","author":"Hough","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.012_bib80","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood.2021014735","article-title":"Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A","volume":"140","author":"Batty","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.012_bib81","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2005-12-5115","article-title":"Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.012_bib82","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2003-01-0292","article-title":"Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector","volume":"102","author":"Scallan","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.012_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101159","article-title":"Analysis of vector genome integrations in multicentric lymphoma after AAV gene therapy in a severe hemophilia A dog","volume":"31","author":"Van Gorder","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2024.07.012_bib84","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nm.3230","article-title":"A\u00a0largely random AAV integration profile after LPLD gene therapy","volume":"19","author":"Kaeppel","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2024.07.012_bib85","article-title":"Molecular characterization of recombinant AAV5 encoding FVIII after human administration","volume":"33","author":"Eggan","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib86","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1210\/jc.2011-3002","article-title":"Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients","volume":"97","author":"Carpentier","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jtha.2024.07.012_bib87","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/hum.2015.136","article-title":"Recombinant adeno-associated virus vector genomes take the form of long-lived, transcriptionally competent episomes in human muscle","volume":"27","author":"Schnepp","year":"2016","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib88","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jhep.2016.05.012","article-title":"Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria","volume":"65","author":"D'Avola","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jtha.2024.07.012_bib89","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2024.07.012_bib90","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ymthe.2019.12.009","article-title":"Retroviral insertional mutagenesis in humans: evidence for four genetic mechanisms promoting expansion of cell clones","volume":"28","author":"Bushman","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib91","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.012_bib92","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1182\/bloodadvances.2023009876","article-title":"Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B","volume":"7","author":"Schmidt","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.07.012_bib93","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/j.ymthe.2023.08.013","article-title":"Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec","volume":"31","author":"Retson","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.07.012_bib94","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/hae.14936","article-title":"Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment","volume":"30","author":"Symington","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.012_bib95","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2023-186891","article-title":"Stable therapeutic transgenic FIX levels for more than 10 years in subjects with severe hemophilia B who received scAAV2\/8-LP1-Hfixco adeno-associated virus gene therapy","volume":"142","author":"Reiss","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.012_bib96","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1111\/jth.15023","article-title":"rare bleeding disorders. Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: communication from the SSC of the ISTH","volume":"18","author":"Konkle","year":"2020","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362400429X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362400429X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T20:57:51Z","timestamp":1762030671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362400429X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":96,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S153878362400429X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.07.012","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adeno-associated viral vector integration: implications for long-term efficacy and safety","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}